母亲维生素D3补充对HIV感染坦桑尼亚孕妇的母体健康、出生结局和婴儿生长的影响:一项随机对照试验的研究方案
ToV5是一项在坦桑尼亚达累斯萨拉姆开展的个体随机、双盲、安慰剂对照试验,纳入2300名接受三联抗逆转录病毒治疗(Option B+方案)的HIV感染孕妇,随机接受每日3000 IU维生素D3或匹配安慰剂,从妊娠12-27周随机化至产后12个月试验出院。主要疗效结局为母体HIV疾病进展或死亡、小于胎龄儿(SGA)出生风险及1岁时婴儿生长迟缓风险,主要安全性结局为母体高钙血症发生率。
要点
- ToV5纳入2300名HIV感染孕妇,随机接受每日3000 IU维生素D3或安慰剂至产后12个月。
- 主要疗效结局:母体HIV疾病进展或死亡、SGA出生风险、1岁时婴儿生长迟缓风险。
- 主要安全性结局为母体高钙血症发生率。
核心结论
- ToV5将提供维生素D3补充对HIV进展和死亡、SGA出生及1岁时婴儿生长迟缓影响的因果证据。
- 试验结果可能可推广至采用Option B+方案的资源有限地区HIV感染孕妇及其子女。
研究设计与样本
- ToV5为个体随机、双盲、安慰剂对照试验,在坦桑尼亚达累斯萨拉姆开展。
- 纳入2300名接受三联抗逆转录病毒治疗(Option B+方案)的HIV感染孕妇,孕周12-27周。
- 随机分为每日3000 IU维生素D3组(从妊娠随机化至产后12个月试验出院)或匹配安慰剂组。
- 孕期每月门诊随访,分娩时随访,产后每月母婴门诊随访。
主要发现
- 原文为研究方案,未报告试验结果。
关键数值与推荐
- 主要疗效结局:母体HIV疾病进展或死亡、小于胎龄儿(SGA)出生风险、1岁时婴儿生长迟缓风险。
- 主要安全性结局:母体高钙血症发生率。
- 次要结局包括一系列母体及儿童临床和生物学健康结局。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Vitamin D has significant immunomodulatory effects on both adaptive and innate immune responses. Observational studies indicate that adults infected with HIV with low vitamin D status may be at increased risk of mortality, pulmonary tuberculosis, and HIV disease progression. Growing observational evidence also suggests that low vitamin D status in pregnancy may increase the risk of adverse birth and infant health outcomes. As a result, antiretroviral therapy (ART) adjunct vitamin D3 supplementation may improve the health of HIV-infected pregnant women and their children. METHODS/DESIGN: The Trial of Vitamins-5 (ToV5) is an individually randomized, double-blind, placebo-controlled trial of maternal vitamin D3 (cholecalciferol) supplementation conducted among 2300 HIV-infected pregnant women receiving triple-drug ART under Option B+ in Dar es Salaam, Tanzania. HIV-infected pregnant women of 12-27 weeks gestation are randomized to either: 1) 3000 IU vitamin D3 taken daily from randomization in pregnancy until trial discharge at 12 months postpartum; or 2) a matching placebo regimen. Maternal participants are followed-up at monthly clinic visits during pregnancy, at delivery, and then with their children at monthly postpartum clinic visits. The primary efficacy outcomes of the trial are: 1) maternal HIV disease progression or death; 2) risk of small-for-gestational age (SGA) births; and 3) risk of infant stunting at 1 year of age. The primary safety outcome of the trial is incident maternal hypercalcemia. Secondary outcomes include a range of clinical and biological maternal and child health outcomes. DISCUSSION: The ToV5 will provide causal evidence on the effect of vitamin D3 supplementation on HIV progression and death, SGA births, and infant stunting at 1 year of age. The results of the trial are likely generalizable to HIV-infected pregnant women and their children in similar resource-limited settings utilizing the Option B+ approach. TRIAL REGISTRATION: ClinicalTrials.gov identifier: NCT02305927 . Registered on 29 October 2014.
引用
- Sudfeld CR, Manji KP, Duggan CP, et al. Effect of maternal vitamin D3 supplementation on maternal health, birth outcomes, and infant growth among HIV-infected Tanzanian pregnant women: study protocol for a randomized controlled trial. Trials. 2017. PMID: 28870263. doi:10.1186/s13063-017-2157-3
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。